TransTech Pharma Selects Genedata to Enhance High Throughput Screening Analysis
News Dec 14, 2005
Genedata has announced that TransTech Pharma has signed a multi-year license for high throughput screening analysis software Genedata Screener®.
Scientists at TransTech Pharma will use Screener to enhance their efforts to develop small molecules as therapeutics for treating human diseases.
"We sought a solution that could be deployed seamlessly with our drug discovery workflow," explained Dr. Robert Rothlein, Senior VP Biology at TransTech Pharma, Inc.
Screener has been integrated with TransTech Pharma’s IT and screening infrastructure. It will automate data quality evaluation and standardize the analysis of compound bioactivity.
Dr. Robert added, "Genedata’s solution saves time and cost in the lead discovery workflow."
"Screener’s modular design and open architecture were important factors in the success of our deployment at TransTech Pharma," says Dr. Michael Lindemann, Business Head Genedata Screener.
TransTech Pharma have developed a highly parallel and integrated Translational Technology® that links together drug design, synthesis and screening.
"We are able to support and enhance this workflow without resource-intensive customization of the Screener platform."
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Targeting a Leaky Protein that Causes ParalysisNews
A rare genetic disorder in which people are overcome suddenly with profound muscle weakness is caused by a hole in a membrane protein that allows sodium ions to leak across cell membranes. Compounds containing a chemical group called guanidinium can block the pore created by the mutation and stop the sodium leak without altering the voltage sensor’s ability to function.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018